Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Express Scripts
McKinsey
Boehringer Ingelheim
Baxter

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

Rituximab - Biologic Drug Details

See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for rituximab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
AstraZenecaPhase 3
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityPhase 2
Washington University School of MedicinePhase 1/Phase 2

See all rituximab clinical trials

Recent Litigation for rituximab

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12
CELGENE CORPORATION v. APOTEX INC.2019-06-19
Genentech, Inc. v. Pfizer Inc.2019-04-05

See all rituximab litigation

PTAB Litigation
PetitionerDate
Celltrion, Inc.2018-05-04
Apotex Inc.2018-02-23
Forty Seven, Inc.2018-01-08

See all rituximab litigation

Pharmacology for rituximab

Patent Text Search: US Patents for rituximab

These patents were identified by searching patent claims

Supplementary Protection Certificates for rituximab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015 00021 Denmark   Start Trial PRODUCT NAME: IBRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 20141021
2017 00012 Denmark   Start Trial PRODUCT NAME: IBRUTINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 C(2015)4704 20150707
/2015 Austria   Start Trial PRODUCT NAME: IBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ; REGISTRATION NO/DATE: EU/1/14/945 20141021
2015000027 Germany   Start Trial PRODUCT NAME: LBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945 20141021
2017 00053 Denmark   Start Trial PRODUCT NAME: ANTISTOF-LAEGEMIDDEL-KONJUGAT, HVORI ET CD22-RETTET ANTISTOF ER KOVALENT BUNDET TIL N-ACETYL-GAMMA-CALICHEAMICIN DIMETHYLHYDRAZID, SVARENDE TIL INOTUZUMAB OZOGAMICIN; REG. NO/DATE: EU/1/17/1200 20170703
2009000070 Germany   Start Trial PRODUCT NAME: RITUXIMAB; NAT. REGISTRATION NO/DATE: EU/1/98/067/001-002 19980602; FIRST REGISTRATION: CH IKS 54378 01 19971127
01730049 Spain   Start Trial PRODUCT NAME: SARILUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/17/1196; DATE OF AUTHORISATION: 20170623; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1196; DATE OF FIRST AUTHORISATION IN EEA: 20170623
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Merck
Medtronic
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.